Figure 2:

Proposed algorithm for selection of SGLT2i based on large clinical trial evidence/indication and threshold of eGFR for initiation based on patient's main complaint (A) and clinical indication (B). Note that current prescribing licences for agents may not apply in all regions. CKD: chronic kidney disease, defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m² or urine albumin-creatinine ratio (uACR) >30 mg/g; HF: heart failure; pEF: preserved ejection fraction; rEF: reduced ejection fraction; DM: Type 2 diabetes mellitus: eGFR values expressed in ml/min/1.73 m², w/: with; wo: without, RCT: randomized controlled trials; KRT: kidney replacement therapy, SGLT2i: sodium-glucose cotransporter-2 inhibitor; ASCVD: atherosclerotic cardiovascular disease.